An Open Label, Drug-drug Interaction Study to Assess the Effect of Multiple Doses of Gemfibrozil on the Single Dose Pharmacokinetics of ASP3652 and to Assess the Effect of Multiple Doses of ASP3652 on the Single Dose Pharmacokinetics of Repaglinide
Latest Information Update: 14 Jan 2020
At a glance
- Drugs ASP 3652 (Primary) ; Gemfibrozil (Primary) ; Repaglinide (Primary)
- Indications Hyperlipidaemia; Interstitial cystitis; Prostatitis; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Astellas Pharma Europe Ltd
- 26 Feb 2013 New trial record